Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

Clinical trial NCT06869473 · RECRUITING

Trial details

NCT number: NCT06869473
Sponsor: Gruppo Oncologico del Nord-Ovest
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma (HNSCC)Recurrent Head and Neck Cancer Metastatic Head and Neck Cancer

Start date: 2025-02-20
Primary completion: 2027-08-20
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.